However, the phase 3 CheckMate 025 trial demonstrated that even if the expression of PD-L1 (≥1%) in RCC is associated with poorer survival, the benefit of therapy is independent of PD-L1 status. The gene discussed is CD274; the disease is renal cell carcinoma.